- Morning Sickness
- Drugs in Pregnancy
- Alcohol, Nicotine, Substance Use
- Folic Acid
- Breastfeeding & Drugs
- Cancer in Pregnancy
- HIV and HIV Treatment
- Conditions in Pregnancy
- Infectious Diseases in Pregnancy
- Nutrition
- Occupational & Environmental Exposures
- Pharmacokinetics/ Drug Metabolism
- PregTox
- The ReproPsych Group
- CAS Newsletter
National sponsor of the Motherisk Program
Our Helplines
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Sept.
5
2013
St. John's,NL
2013 FACE meeting
June
23
2013
Orlando, Florida
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting
.
-
Jul192012
-
Mar292012
-
Jul282011
-
Jan272011
- Read more in our News Archive
Current Studies at Motherisk
-
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
-
Pregnancy in Women with Multiple Sclerosis
-
Environmental Exposures and Children's Health
-
Alcohol Use during Pregnancy
-
Control of Hypertension in Pregnancy Study
-
Folic Acid Before and During Pregnancy
-
Lamisil in Pregnancy
-
Meridia in Pregnancy
-
Autoimmune Diseases in Pregnancy Project
The Cancer in Pregnancy Forum
Archived Questions and AnswersThis Forum has been the centre of an exceptional exchange of knowledge diagnosis, treatment, symptoms and other effects of cancer during pregnancy and lactation. All are welcome to review the Questions and Answers posted here, provided that they acknowledge and accept the important proviso and disclaimer below.
Dose-modifications for antineoplastics during pregnancy
CCoPE
Date: 2003-05-22
Question:
Dosing of antineoplastic drugs during pregnancy:
Several reviews exist in which possible changes in the pharmacokinetics of antineoplastic agents are described (Volume of distribution, Clearance, amniotic fluid as a "third space" etc.). Are there any recommendations or dose-modifications for antineoplastics during pregnancy with respect to the above mentioned pharmacokinetic changes? Is the current body-weight or the weight before pregnancy used for calculation of body-surface ?
Answer:
Pregnancy is indeed associated with various pharmacokinetic changes. Even with regard to non-cancer conditions, very few drugs have been formally compared in
pregnancy vs. postpartum. Presently we are not aware of any such studies
with cancer chemotherapy in pregnancy. Consequently, there are no changes
in dose guidelines for pregnancy. One may hypothesize that for most agents, either renally or hepatically eliminated, levels in pregnancy will be lower and potentially,
effect may decrease.
![[Valid RSS]](/images/rssValid.png "Validate my RSS feed")